Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings.
加利福尼亚州布里斯班，2025年1月7日（全球新闻社）-- Vera Therapeutics, Inc.（纳斯达克：VERA）是一家处于临床后期的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的变革性治疗。今天，公司管理团队宣布将参加第43届年度摩根大通医疗健康大会，会议将在2025年1月12日至16日在加州旧金山举行。管理团队还将参加一对一的投资者会议。
Presentation Details:
Date: Monday, January 13, 2025
Time: 4:30 PM PST
Webcast:
展示详情：
日期：2025年1月13日，星期一
时间：下午4:30 太平洋标准时间
网络直播：
A replay of the event will be available for 90 days and can be accessed by visiting the "Investor Calendar" section of the Vera Therapeutics website.
活动回放将在90天内提供，您可以通过访问Vera Therapeutics网站的“投资者日历”部分进行访问。
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit .
关于Vera
Vera Therapeutics是一家处于临床后期的生物技术公司，专注于开发严重免疫疾病的治疗方案。Vera的使命是推动针对免疫疾病根源的治疗，以改变患者的护理标准。Vera的主要产品候选药物是atacicept，这是一种每周自我注射一次的融合蛋白，作为皮下注射使用，能够阻断b细胞激活因子(BAFF)和诱导增殖配体(APRIL)，这两者刺激b细胞和浆细胞产生自体抗体，从而导致某些自身免疫疾病，包括IgAN，也称为Berger病，以及狼疮性肾炎。此外，Vera还在评估atacicept可能在其他疾病中减少自体抗体的医学用途。Vera还在开发MAU868，这是一种单克隆抗体，旨在中和BK病毒(BKV)感染，BK病毒是一种多瘤病毒，在某些情况下如肾移植中可能产生严重后果。Vera保留atacicept和MAU868的所有全球开发和商业权利。欲了解更多信息，请访问。
For more information, please contact:
如需更多信息，请联系：
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
投资者联系人：
乔伊斯·阿拉尔
LifeSci顾问
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
媒体联系人：
梅德琳·霍廷
通信-半导体
MHawtin@lifescicomms.com
